Get started
Work

Making Anti-CD19 CAR-T Cell Therapy Accessible and Affordable: First-in-Human Phase I Clinical Trial Experience from India

Year: 2022
Type: article
Study design: Clinical Trial
Source: Blood
DOI: 10.1182/blood-2022-168928
Authors: Atharva Karulkar, Hasmukh Jain, Shreshtha Shah, Aalia Khan, Ankesh Jaiswal, Afrin Firfiray, Prashant Suvasia, Priyanshi Suvasia, Juber Pendhari, Sweety Asija, Ambalika Chowdury, Ankit Banik, Smrithi Ravikumar, Neha Sharma, Minal Poojary, Sumathi Hiregoudar, Preeti Desai, Anisha Navkudkar, Sunil Rajadhyaksha, Jayashree Thorat, Prashant R. Tembhare, Albeena Nisar, Manju Sengar, David F. Stroncek, Steven Highfill, Nirali N. Shah, Gaurav Narula, Rahul Purwar
Institutions: Indian Institute of Technology Bombay, Tata Memorial Hospital, Homi Bhabha National Institute, Advanced Centre for Treatment, Research and Education in Cancer, National Institutes of Health, National Cancer Institute
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: closed
OpenAlex ID: W4310112911
FWCI: 1.185
Cites:
Cited by: 13
Related to: 10